echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Eur J Cancer: More than half of patients treated with dabrafenib combined with trametinib will experience fever!

    Eur J Cancer: More than half of patients treated with dabrafenib combined with trametinib will experience fever!

    • Last Update: 2021-08-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The combination of dabrafenib and trametinib has been approved by the US FDA , the European Society and the Australian TGA for the treatment of unresectable or metastatic melanoma with BRAF V600 mutation, and as an adjuvant therapy for resected BRAF V600 Mutant stage 3 melanoma and BRAF V600 mutant advanced non-small cell lung cancer ( NSCLC ).
    In addition, this combination program has also been approved by the FDA and TGA for the treatment of BRAF V600 mutant undifferentiated thyroid cancer
    .

    FDA NSCLC

    Fever is a common adverse event in patients receiving dabrafenib combined with trametinib
    .


    This article describes the acceptance of tadalafil Nepal + incidence in patients treated with imatinib Qumei fever, models and in clinical trials management situation


    management

    A total of 1,075 patients receiving dabrafenib combined with trametinib in clinical trials were included: 82 advanced NSCLC (phase 2 trial), 435 resectable stage 3 melanomas (phase 3 COMBI-AD study) , 209 unresectable melanomas (phase 3 COMBI-d study) and 350 metastatic melanomas (phase 3 COMBI-v study)
    .

    Proportion of patients with different repetition times of fever

    Proportion of patients with different repetition times of fever

    Among the 1076 patients participating in the clinical trial, 61.
    3% had fever, 5.
    7% had grade 3/4 fever, and 15.
    6% had serious fever events as defined by the agreement
    .


    Among the 660 patients with fever, 33.


    Among the 660 patients with fever, 33.


    In summary, fever is the most common adverse event in treatment with dabrafenib combined with trametinib.


    Original source:

    Schadendorf Dirk,Robert Caroline,Dummer Reinhard et al.


    Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.